“…ETAR promotes vasoconstriction, cell growth, adhesion and thrombosis, while ETBR promotes vasodilation [ 10 , 11 , 12 ]. Endothelin receptor antagonists have been developed for the treatment of multiple cardiovascular diseases, such as hypertension and systemic sclerosis [ 10 , 13 , 14 , 15 ]. Moreover, they also show therapeutic action for glaucoma [ 16 ], preeclampsia [ 17 ], diabetic kidney disease [ 18 ] and ovarian tumors [ 19 ].…”